Related Experiment Videos
Guidelines for the treatment of hypertension: a critical review
1Janssen Research Foundation, Beerse, Belgium.
Cardiovascular Drugs and Therapy
|August 1, 1994
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
A comparison and an investigation of a potential synergistic effect of labetalol and bethanidine in patients with mild hypertension.
British journal of clinical pharmacology·2015
A critique of hypertension treatment trials and of their evaluation.
Journal of evaluation in clinical practice·2001
Which antihypertensive drug classes have been shown to be beneficial? What are their benefits? A critique of hypertension treatment trials.
Cardiovascular drugs and therapy·2000
The modern treatment of hypertension.
Journal of human hypertension·2000
Nebivolol versus enalapril in essential hypertension: a long-term double-blind comparative trial.
Acta clinica Belgica·1999
Nebivolol versus nifedipine in the treatment of essential hypertension: a double-blind, randomized, comparative trial.
American journal of therapeutics·1999
Liraglutide Ameliorates Atrial Fibrillation in Association with Enhanced Adiponectin Signaling in Epicardial Adipose Tissue.
Cardiovascular drugs and therapy·2026
Energetic Decoding of VSMC Plasticity: Metabolic Reprogramming and Phenotypic Switching.
Cardiovascular drugs and therapy·2026
Introducing Allopurinol to the Medical Treatment of Marfan Syndrome: Advantages, Limitations, and Potential Extension to other Aortopathies.
Cardiovascular drugs and therapy·2026
Apixaban Versus LMWH in CAT/VTE: A Comment on Clinical and Methodological Heterogeneity.
Cardiovascular drugs and therapy·2026
Dendritic Cells in the Immunoregulation of Myocardial Infarction: Mechanisms and Therapeutic Strategies.
Cardiovascular drugs and therapy·2026
Vascular Immunometabolism in Atherosclerosis: Emerging Roles of Glycometabolic Reprogramming in Immune and Vascular Cells.
Cardiovascular drugs and therapy·2026